Welcome to the trials list!

Some tips to help get started:

  • Click on any trial title to view details, including trial sites, eligibility criteria, and our research about study drugs
  • If the list is long, use the search box and filters on the left to narrow down trials
  • Bookmark trials of interest by clicking the bookmark icon to the right of the trial title
Sign up to save your data! Arrow
Processing... Processing...

Clinical Trials for Other Solid Tumor

Search

Close
[Clear]

Filters

Location:
[Clear]
[Clear]

There are 397 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.

397 trials meet filter criteria.

Sort by:

No known activity More information High burden on patient More information Started >3 years ago More information
Sponsor: AbbVie (industry) Phase: 1 Start date: March 9, 2021

HealthScout AI summary: This trial involves patients with refractory or relapsed locally advanced or metastatic solid tumors, such as HNSCC, NSCLC, and ccRCC, evaluating the investigational drug ABBV-CLS-484, an orally bioavailable inhibitor of PTPN2 and PTPN1 that enhances immune responses, as monotherapy or in combination with PD-1 inhibitors or VEGFR TKIs.

ClinicalTrials.gov ID: NCT04777994

No known activity More information High burden on patient More information Started >3 years ago More information
Sponsor: Helsinn Healthcare SA (industry) Phase: 1/2 Start date: Dec. 16, 2020

HealthScout AI summary: The trial involves patients with advanced solid tumors characterized by RET gene abnormalities, where TAS0953/HM06, a selective RET inhibitor targeting the RET receptor tyrosine kinase, is administered to evaluate safety, dosing, and treatment efficacy. Phase II specifically includes NSCLC patients with RET gene fusion, assessing both those previously treated with RET inhibitors and those who have exhausted existing therapies.

ClinicalTrials.gov ID: NCT04683250

No known activity More information High burden on patient More information Started >3 years ago More information
Sponsor: Precision Biologics, Inc (industry) Phase: 1/2 Start date: Jan. 18, 2019

HealthScout AI summary: This trial enrolls adult patients with chemo-resistant non-small cell lung cancer, head and neck squamous cell carcinoma, cervical, and uterine cancers, who express the NEO-201 antigen, to evaluate the combination of NEO-201, a monoclonal antibody targeting specific cancer cell glycans, with pembrolizumab, to potentially overcome resistance to checkpoint inhibitors.

ClinicalTrials.gov ID: NCT03476681

No known activity More information High burden on patient More information Started >3 years ago More information
Sponsor: Deciphera Pharmaceuticals, LLC (industry) Phase: 1/2 Start date: June 15, 2021

HealthScout AI summary: This trial targets adult patients with advanced or metastatic solid tumors having RAS, NF1, or RAF mutations, evaluating DCC-3116, an oral ULK1/2 inhibitor that blocks autophagy, both as monotherapy and in combination with trametinib, binimetinib, or sotorasib.

ClinicalTrials.gov ID: NCT04892017

No known activity More information High burden on patient More information Started >3 years ago More information
Sponsor: Simcha IL-18, Inc. (industry) Phase: 1/2 Start date: Aug. 6, 2021

HealthScout AI summary: This trial involves adult patients with advanced or metastatic solid tumors such as melanoma and non-small cell lung cancer who have relapsed after standard treatments, testing the investigational agent ST-067 alone or with pembrolizumab and obinutuzumab to enhance immune response against tumor cells.

ClinicalTrials.gov ID: NCT04787042

No known activity More information High burden on patient More information Started >3 years ago More information
Sponsor: VM Oncology, LLC (industry) Phase: 1 Start date: June 8, 2018

HealthScout AI summary: This trial investigates VMD-928, a selective TrkA inhibitor, in adult patients with advanced solid tumors or lymphoma that are resistant to existing therapies, focusing on those with TrkA overexpression or NTRK1 gene fusion.

ClinicalTrials.gov ID: NCT03556228

Low burden on patient More information Started >3 years ago More information Restricted enrollment More information
Sponsor: Novartis Pharmaceuticals (industry) Phase: 4 Start date: Dec. 28, 2017

HealthScout AI summary: This trial focuses on patients with BRAF V600 mutation-positive cancers who have previously shown clinical benefit from and are currently treated with the BRAF inhibitor dabrafenib, the MEK inhibitor trametinib, or their combination in a Novartis or GSK parent study, assessing the long-term safety of these treatments.

ClinicalTrials.gov ID: NCT03340506

First Previous Page 40 of 40
Please help us improve by giving us feedback or feature requests. Email [email protected]
Copy email address
Email copied to clipboard